JP2018526460A5 - - Google Patents

Download PDF

Info

Publication number
JP2018526460A5
JP2018526460A5 JP2018532812A JP2018532812A JP2018526460A5 JP 2018526460 A5 JP2018526460 A5 JP 2018526460A5 JP 2018532812 A JP2018532812 A JP 2018532812A JP 2018532812 A JP2018532812 A JP 2018532812A JP 2018526460 A5 JP2018526460 A5 JP 2018526460A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administered
subject
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532812A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018526460A (ja
JP7001599B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2016/071599 external-priority patent/WO2017046108A1/en
Publication of JP2018526460A publication Critical patent/JP2018526460A/ja
Publication of JP2018526460A5 publication Critical patent/JP2018526460A5/ja
Application granted granted Critical
Publication of JP7001599B2 publication Critical patent/JP7001599B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532812A 2015-09-14 2016-09-13 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法 Active JP7001599B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218433P 2015-09-14 2015-09-14
US62/218,433 2015-09-14
PCT/EP2016/071599 WO2017046108A1 (en) 2015-09-14 2016-09-13 Dactinomycin compositions and methods for the treatment of acute myeloid leukemia

Publications (3)

Publication Number Publication Date
JP2018526460A JP2018526460A (ja) 2018-09-13
JP2018526460A5 true JP2018526460A5 (enExample) 2019-10-17
JP7001599B2 JP7001599B2 (ja) 2022-01-19

Family

ID=56896582

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532812A Active JP7001599B2 (ja) 2015-09-14 2016-09-13 急性骨髄性白血病の処置のためのダクチノマイシン組成物および方法

Country Status (7)

Country Link
US (2) US10335416B2 (enExample)
EP (1) EP3349759B1 (enExample)
JP (1) JP7001599B2 (enExample)
AU (1) AU2016324920B2 (enExample)
CA (1) CA2998042C (enExample)
ES (1) ES2809805T3 (enExample)
WO (1) WO2017046108A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2809805T3 (es) 2015-09-14 2021-03-05 Brunangelo Falini Composiciones de dactinomicina y métodos para el tratamiento de la leucemia mieloide aguda
EP3512560A4 (en) 2016-09-13 2020-05-27 Rasna Research Inc. DACTINOMYCIN COMPOSITIONS AND METHOD FOR TREATING MYELODYSPLASTIC SYNDROME AND ACUTE MYELOIC LEUKEMIA
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
CN113164443A (zh) * 2018-09-26 2021-07-23 库拉肿瘤学公司 用多发性内分泌抑癌蛋白抑制剂治疗血液系统恶性肿瘤
BR112021016522A2 (pt) 2019-02-22 2021-10-26 Hanmi Pharm. Co., Ltd. Composição farmacêutica para o tratamento da leucemia mieloide aguda
AU2020308814A1 (en) 2019-06-27 2022-02-03 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
WO2023163508A1 (ko) * 2022-02-28 2023-08-31 한국유나이티드제약 주식회사 향상된 용해도를 가지는 닥티노마이신 함유 약학조성물의 제조방법
CN120857931A (zh) * 2022-12-10 2025-10-28 艾普托斯生物科学公司 用于治疗患有血液学恶性病的患者的方法
CN116942834B (zh) * 2023-06-12 2024-04-05 新乡医学院 包含核仁应激诱导剂的抗肿瘤药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
GB0223341D0 (en) 2002-10-08 2002-11-13 Groningen Acad Ziekenhuis Organic compounds
US20070010465A1 (en) * 2005-07-06 2007-01-11 Branimir Sikic Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
EP2397149A1 (en) * 2010-06-17 2011-12-21 Hil-Invent Ges.M.B.H. Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p)
WO2015101618A1 (en) * 2013-12-30 2015-07-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination of an arsenic compound and at least one retinoid for treating acute myeloid leukemia
ES2809805T3 (es) 2015-09-14 2021-03-05 Brunangelo Falini Composiciones de dactinomicina y métodos para el tratamiento de la leucemia mieloide aguda

Similar Documents

Publication Publication Date Title
JP2018526460A5 (enExample)
JP2006501240A5 (enExample)
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
JP2025020134A5 (enExample)
NO20014842L (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
JP2013155188A5 (enExample)
FI3773715T3 (fi) Mirikitsumabi haavaisen paksusuolitulehduksen hoitamisessa
RU2018134167A (ru) Комбинированная терапия для лечения острого миелоидного лейкоза
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
JP2017501154A5 (enExample)
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
RU2016149316A (ru) Лечение ревматоидного артрита
ZA202210633B (en) Methods for dose initiation of aripiprazole treatments
MX2024006799A (es) Metodos para el tratamiento de cáncer con prame positivo.
ATE546136T1 (de) Kardioprotektions- und neuroprotektionsverfahren durch intravenöse verabreichung von halogenierten flüchtigen narkosemitteln
JOP20190019A1 (ar) تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
JP2016505050A5 (enExample)
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
Cheon et al. Treatment of nail lichen Striatus with Intralesional steroid injection: A case report and literature review.
Mahmoud Octreotide can control lymphorrhea after axillary node dissection in mastectomy operations
JP2016510738A5 (enExample)
JP2020524167A5 (enExample)
JPWO2021070054A5 (enExample)
CN110604729B (zh) 双硫仑联合葡萄籽原花青素在制备用于治疗弥漫性大b细胞淋巴瘤药物方面的应用